Dr. John Berkenbosch, MD
Claim this profileNorton Children's Hospital: University of Louisville
Studies Critical Illness
Studies Pressure Sore
4 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials John Berkenbosch, MD is currently running
Hydrocortisone
for Pediatric Septic Shock
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).
Recruiting1 award Phase 3
"PICU Up!" Early Mobility Intervention
for Critically Ill Children
While mortality in U.S. pediatric intensive care units (PICUs) is improving, surviving children frequently develop persistent physical, cognitive, and psychological impairments. Over half of critically ill children experience potentially preventable PICU-acquired morbidities, with mechanically ventilated children being at greatest risk. In critically ill adults, randomized trials have shown that progressive mobility, started early (within 3 days of initiating mechanical ventilation), decreases muscle weakness and the duration of mechanical ventilation. However, similar randomized studies have not been conducted in the PICU. The investigator's prior studies revealed that less than 10 percent of critically ill children at the highest risk of functional decline are evaluated by a physical or occupational therapist within 3 days of PICU admission. Given the interplay of sedation, delirium, sleep, and immobility in the PICU, single-component interventions, such as sedation protocolization, have not consistently shown benefit for decreasing mechanical ventilation duration. Thus, the investigators developed the first pediatric-specific, interprofessional intervention (PICU Up!) to integrate goal-directed sedation, delirium prevention, sleep promotion, and family engagement into daily PICU care in order to facilitate early and progressive mobility. The investigators have demonstrated the safety and feasibility of this pragmatic, multifaceted strategy in both single-site and multicenter pilot studies. Hence, the next phase of the investigators research is to evaluate the clinical effectiveness and delivery of the PICU Up! intervention across a range of PICU patients and health systems. The investigators propose a pragmatic, stepped-wedge, cluster randomized controlled trial that will include 10 academic and community hospitals in the United States, with the following Aims: 1) Evaluate if the PICU Up! intervention, delivered under real-world conditions, decreases mechanical ventilation duration (primary outcome) and improves delirium and functional status compared to usual care in critically ill children; and 2) Conduct a multi-stakeholder, mixed-methods process evaluation to identify key contextual factors associated with delivery of PICU Up!. If proven effective, the PICU Up! intervention has potential to profoundly change medical care in the PICU and substantially impact public health by improving outcomes for the growing number of pediatric survivors of critical illness.
Recruiting1 award N/A1 criteria
More about John Berkenbosch, MD
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments John Berkenbosch, MD has experience with
- PICU Up!
- Hydrocortisone
- Magnesium Sulfate
Breakdown of trials John Berkenbosch, MD has run
Critical Illness
Acquired Weakness
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Berkenbosch, MD specialize in?
John Berkenbosch, MD focuses on Critical Illness and Pressure Sore. In particular, much of their work with Critical Illness has involved treating patients, or patients who are undergoing treatment.
Is John Berkenbosch, MD currently recruiting for clinical trials?
Yes, John Berkenbosch, MD is currently recruiting for 2 clinical trials in Louisville Kentucky. If you're interested in participating, you should apply.
Are there any treatments that John Berkenbosch, MD has studied deeply?
Yes, John Berkenbosch, MD has studied treatments such as PICU Up!, Hydrocortisone, Magnesium Sulfate.
What is the best way to schedule an appointment with John Berkenbosch, MD?
Apply for one of the trials that John Berkenbosch, MD is conducting.
What is the office address of John Berkenbosch, MD?
The office of John Berkenbosch, MD is located at: Norton Children's Hospital: University of Louisville, Louisville, Kentucky 40202 United States. This is the address for their practice at the Norton Children's Hospital: University of Louisville.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.